Sustainability is no longer a peripheral consideration in biomanufacturing. It has become a strategic imperative, shaped not only by regulatory requirements but also by customer expectations, investor priorities, and the growing need for resilient global supply chains.
Across the biopharmaceutical industry, companies are under increasing pressure to deliver innovative therapies quickly while demonstrating measurable environmental progress. Net-zero commitments, science-based targets, and evolving ESG expectations are no longer aspirational— they are influencing investment decisions, supplier selection, and the way therapies are developed and manufactured.
Yet while ambition has accelerated, implementation remains uneven. Many organisations continue to focus on visible operational improvements such as energy efficiency, packaging, and logistics. These initiatives remain important, but they represent only part of the solution. Some of the greatest opportunities to reduce environmental impact are determined much earlier—through decisions made during process development, technology selection, and supplier collaboration. This requires a shift in mindset: treating sustainability not as an operational afterthought, but as a design principle embedded into the scientific and operational decisions that shape manufacturing from the outset.
The Growing Importance of Supply Chains
As sustainability expectations continue to evolve, the focus is expanding beyond individual facilities to the broader value chain. For many biopharmaceutical companies, the majority of emissions occur outside their own operations—in raw materials, manufacturing inputs, and logistics networks. Addressing these Scope 3 emissions requires greater transparency and closer collaboration across the supply chain, making suppliers increasingly important partners in helping manufacturers understand, measure, and reduce environmental impact.
As a bioprocessing technology provider, we are seeing these expectations become an integral part of customer conversations. Sustainability is no longer viewed solely through the lens of manufacturing operations; it is increasingly influencing supplier selection, technology adoption, and long-term investment decisions.
Why Early-stage Decisions Matter
While supply chain transparency provides greater visibility into environmental impact, meaningful reductions are ultimately achieved through the decisions made during process development. The greatest sustainability gains in biomanufacturing are often determined long before a facility begins commercial production.
By considering sustainability alongside Quality by Design (QbD) principles and collaborating early with technology partners, manufacturers can optimise resource use, reduce waste, improve manufacturing efficiency, and avoid costly redesigns later in development.
This thinking is already driving innovation across the bioprocessing workflow, demonstrating that process intensification and sustainability can reinforce one another rather than compete. For example:
• Higher-capacity affinity chromatography media improve purification efficiency through fewer processing cycles and longer media lifetimes while reducing buffer consumption and cleaning requirements.
• Inline conditioning systems prepare buffers on demand, lowering water and energy consumption, reducing plastic waste, and improving manufacturing flexibility.
• Advanced filtration technologies, including low-fouling filters and ready-to-use assemblies, simplify operations, minimise waste, and reduce the risk of batch failures.
• Continuous processing approaches, such as single-pass tangential flow filtration, improve process efficiency while lowering buffer consumption and energy demand.
Viewed individually, these innovations may deliver incremental gains. Together, they illustrate how sustainability can be designed into manufacturing from the earliest stages, creating cumulative environmental and operational benefits throughout a product's lifecycle.
Looking Beyond Process Performance
Sustainability should be evaluated across the full lifecycle of bioprocessing technologies—from raw material sourcing and manufacturing to distribution, product lifetime, and end-of-life. Life cycle assessment (LCA) is helping manufacturers understand where environmental impacts occur and where meaningful improvements can be made. In chromatography, for example, optimising a Protein A capture step alongside advances in resin technology and process design has been shown to reduce associated CO₂e emissions by up to 90 per cent.
Beyond process optimisation, improvements in responsible sourcing, renewable energy adoption, water stewardship, circularity, and logistics are helping reduce the environmental footprint of resin manufacturing. Together, these efforts demonstrate that sustainable biomanufacturing is achieved through cumulative improvements across the lifecycle—not a single breakthrough technology.
APAC's Opportunity to Shape The Future of Sustainable Biomanufacturing
APAC is entering a unique phase in the evolution of biomanufacturing. Although maturity varies across the region, markets such as South Korea, Singapore, and China are investing heavily in advanced manufacturing, digitalisation, and next-generation production capabilities. At the same time, many facilities are still being expanded or built, creating a unique opportunity to embed sustainability into process design, facility planning, and supply chain strategies from the outset.
The region's growing role in global biologics manufacturing is also changing customer expectations. Increasingly, companies are looking beyond manufacturing capacity and cost competitiveness, placing greater emphasis on transparent sustainability practices, resilient supply chains, and measurable environmental performance. Sustainability is becoming a competitive differentiator rather than simply a compliance requirement.
This shift is already evident among industry leaders. Companies such as Samsung Biologics have established net-zero roadmaps while implementing product carbon footprint methodologies, and WuXi AppTec has aligned its sustainability strategy with global initiatives such as the Science Based Targets initiative. At the same time, collaborative efforts such as the Sustainable Markets Initiative demonstrate growing recognition that reducing emissions across the biopharmaceutical value chain will require collective action rather than isolated efforts.
For APAC, this presents an opportunity to lead rather than follow. By embedding sustainability into new manufacturing capacity, supplier ecosystems, and process innovation from the beginning, the region can help define the next generation of resilient and sustainable biomanufacturing.
From Strategy to Implementation
Setting sustainability ambitions is only the first step. The greater challenge for the biopharmaceutical industry is turning those ambitions into practical, scalable actions that deliver measurable environmental and operational benefits.
Implementing sustainability at commercial scale requires balancing environmental goals with the realities of regulated manufacturing. Quality, reliability, and patient safety remain non-negotiable, meaning sustainability initiatives must seamlessly integrate into existing processes without compromising performance or introducing operational risk. Increasingly, manufacturers are seeking solutions that improve resource efficiency, strengthen supply chain resilience, and reduce environmental impact while maintaining productivity and process consistency.
Across APAC, these principles are already being translated into tangible operational improvements. At Cytiva's manufacturing site in Pune, India, water consumption was reduced by 29% yearon-year despite production volumes doubling—demonstrating that operational growth and resource stewardship can go hand in hand.
Similar progress can be seen across Cytiva's manufacturing network. In China, the Tonglu facility has been recognised for its low-carbon manufacturing and energy efficiency initiatives, while wastewater reuse systems at the Beijing site are helping reduce daily water consumption through practical, localised solutions. Meanwhile, renewable energy investments across Singapore, Pune, and Tauranga are supporting decarbonisation, with the Tauranga site returning approximately 13,000 kWh of solar-generated electricity to the grid while contributing to local energy resilience.
These examples demonstrate that sustainability is rarely achieved through a single breakthrough. Rather, incremental improvements across water stewardship, renewable energy, and operational efficiency can collectively reduce environmental impact while strengthening manufacturing performance.
The same principle is shaping the next generation of biomanufacturing infrastructure. Cytiva's planned Innovation Hub in Korea's Songdo Bio Cluster has been designed with sustainability integrated from the outset, incorporating energy and water efficiency measures, emissions reduction strategies, and waste minimisation practices aligned with net-zero ambitions. The hub is also intended to bring together customers, technologies, and expertise to accelerate more sustainable bioprocess development across the region.
These examples reflect a broader shift taking place across APAC. Sustainability is no longer being considered only once facilities are operational, it is increasingly being embedded into manufacturing strategies, infrastructure, and innovation ecosystems from the very beginning.
Collaboration will Determine The Pace of Change
No single organisation can achieve sustainable biomanufacturing alone. Meaningful progress will depend on collaboration across the entire ecosystem, bringing together manufacturers, suppliers, regulators, and technology partners to address shared sustainability challenges.
Suppliers have an increasingly strategic role to play—not only by developing innovative technologies, but also by providing the data, transparency, and technical expertise needed to help manufacturers understand and reduce emissions across their processes. Shared approaches to carbon accounting, life cycle assessment, and sustainability reporting will also be essential to building greater consistency and accelerating progress across global supply chains.
Ultimately, sustainable biomanufacturing is a collective effort. The organisations that make the greatest progress will be those that treat sustainability as a shared responsibility across the value chain rather than the responsibility of any single stakeholder.
Looking Ahead
Sustainable biomanufacturing will not be defined by a single technology or initiative. It will be shaped by the decisions made across process development, manufacturing, supplier partnerships, and infrastructure planning. The next phase of the industry's sustainability journey is therefore less about setting new ambitions and more about embedding sustainability into the scientific, operational, and commercial decisions that shape manufacturing from the outset. By combining process innovation, lifecycle thinking, and collaboration across the value chain, biopharmaceutical companies can build manufacturing systems that are not only more environmentally responsible, but also more resilient, efficient, and prepared for the future.
Read the full article — it's free
Register with Pharma Focus Asia to unlock expert insights, research articles and in-depth industry analysis.
